연구성과로 돌아가기

2021 연구성과별 연구자 정보 (137 / 2991)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Lee, Je-Jung Lee, JJ 9 Chonnam Natl Univ, Hwasun Hosp, Dept Internal Med, Gwangju, South Korea F-6974-2013 Lee, Jung-Hye zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Choi, SeungHyun Choi, S 10 Chonnam Natl Univ, Hwasun Hosp, Genom Res Ctr Hematopoiet Dis, Jeollanam, South Korea zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Lee, Ja-Yeon Lee, JY 11 Chonnam Natl Univ, Hwasun Hosp, Genom Res Ctr Hematopoiet Dis, Jeollanam, South Korea zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Park, Seong-Kyu Park, SK 12 Soon Chun Hyang Univ Hosp, Dept Hematol Oncol, Bucheon, South Korea zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Moon, Joon Ho Moon, JH 13 Kyungpook Natl Univ, Dept Hematol Oncol, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Lee, Hui Young Lee, HY 14 Kangwon Natl Univ, Kangwon Natl Univ Hosp, Sch Med, Dept Internal Med, Chunchon, South Korea zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Lee, Hui Young Lee, HY 14 Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Kim, Kyoung Ha Kim, KH 15 Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Kim, Kyoung Ha Kim, KH 15 Soonchunhyang Univ Hosp, Dept Internal Med, Seoul, South Korea zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Cai, Yu Cai, Y 16 Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Cai, Yu Cai, Y 16 Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Hematol, Shanghai 200080, Peoples R China zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Yi, Seong Yoon Yi, SY 17 Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Yi, Seong Yoon Yi, SY 17 Inje Univ, Ilsan Paik Hosp, Dept Internal Med, Goyang Si, South Korea zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Novitzky-Basso, Igor Novitzky-Basso, I 18 Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada AAU-2356-2020 Novitzky-Basso, Igor 0000-0003-3748-3117 Novitzky-Basso, Igor zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing Zhang, Zhaolei Zhang, ZL 19 교신저자 Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada G-2369-2017 Zhang, Zhaolei zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
페이지 이동: